DNA methylation, histone acetylation and methylation of epigenetic modifications as a therapeutic approach for cancers

Cancer Letters

Volumn 373, Issue 2, 2016, Pages 185-192

  Yen, Ching Yu ^a,b   Huang, Hurng Wern ^c   Shu, Chih Wen ^d   Hou, Ming Feng ^e,f   Yuan, Shyng Shiou F ^e   Wang, Hui Ru ^f   Chang, Yung Ting ^c   Farooqi, Ammad Ahmad ^g   Tang, Jen Yang ^e,h,i   Chang, Hsueh Wei ^c,e,f  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g INSTITUTE OF BIOMEDICAL AND GENETIC ENGINEERING IBGE   (Pakistan)

^h KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

ⁱ KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

Author keywords

Acetylation; Epigenetic modification; Histone; Methylation; Sugar metabolism

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE FRUCTOSE 2,3 BISPHOSPHATASE; ALLYLSELENOLCYSTEINE; CAVEOLIN 1; DECITABINE; DNA METHYLTRANSFERASE INHIBITOR; FLAVONOID; FRUCTOSE 1,6 BISPHOSPHATASE 1; FRUCTOSE 1,6 BISPHOSPHATASE 2; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GUADECITABINE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; LACTATE DEHYDROGENASE 2; MICRORNA; N PHTHALOYLTRYPTOPHAN; NADH DEHYDROGENASE(UBIQUINONE) 1 ALPHA SUBCOMPLEX 13; OXIDOREDUCTASE; PHOSPHATASE; PHOSPHOTRANSFERASE; PINOMETOSTAT; PROCAINAMIDE; PYRUVATE KINASE M2; SELENOAMINO ACID; SELISISTAT; TETRAHYDROURIDINE; TRANSKETOLASE LIKE 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNTRANSLATED RNA; ZEBULARINE; HISTONE;

ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; BREAST CANCER; CANCER GROWTH; CARBOHYDRATE METABOLISM; CARCINOGENESIS; COLON CANCER; DNA METHYLATION; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; EPIGENETICS; GENE CONTROL; GLYCOLYSIS; HEAD AND NECK CANCER; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; LEUKEMIA; LIVER CANCER; LUNG CANCER; MOUTH CANCER; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SHORT SURVEY; STOMACH CANCER; ACETYLATION; ANIMAL; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

ACETYLATION; ANIMALS; AUTOPHAGY; CARBOHYDRATE METABOLISM; DNA METHYLATION; EPIGENESIS, GENETIC; GLYCOLYSIS; HISTONES; HUMANS; NEOPLASMS; OXIDATIVE STRESS;

EID: 84958627366     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.01.036     Document Type: Review

References (161)

1. Goldberg A.D., Allis C.D., Bernstein E. Epigenetics: a landscape takes shape. Cell 2007, 128:635-638.
2. Bird A. Perceptions of epigenetics. Nature 2007, 447:396-398.
3. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
4. Berger S.L. The complex language of chromatin regulation during transcription. Nature 2007, 447:407-412.
5. Li B., Carey M., Workman J.L. The role of chromatin during transcription. Cell 2007, 128:707-719.
6. Esteller M. Epigenetics in cancer. N. Engl. J. Med 2008, 358:1148-1159.
7. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
8. Mattick J.S., Makunin I.V. Non-coding RNA. Hum. Mol. Genet 2006, 15(Spec1):R17-R29.
9. Bernstein B.E., Meissner A., Lander E.S. The mammalian epigenome. Cell 2007, 128:669-681.
10. Barbano R., Muscarella L.A., Pasculli B., Valori V.M., Fontana A., Coco M., et al. Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics 2013, 8:105-112.
11. Guo Y., Yu S., Zhang C., Kong A.T. Epigenetic regulation of Keap1-Nrf2 signaling. Free Radic. Biol. Med 2015, 88(Pt B):337-349.
12. Chen T., Li E. Structure and function of eukaryotic DNA methyltransferases. Curr. Top. Dev. Biol 2004, 60:55-89.
13. Bestor T.H. The DNA methyltransferases of mammals. Hum. Mol. Genet 2000, 9:2395-2402.
14. Groth A., Rocha W., Verreault A., Almouzni G. Chromatin challenges during DNA replication and repair. Cell 2007, 128:721-733.
15. Meissner A., Mikkelsen T.S., Gu H., Wernig M., Hanna J., Sivachenko A., et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008, 454:766-770.
16. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet 2007, 39:237-242.
17. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., et al. Epigenetic stem cell signature in cancer. Nat. Genet 2007, 39:157-158.
18. Ruthenburg A.J., Li H., Patel D.J., Allis C.D. Multivalent engagement of chromatin modifications by linked binding modules. Nat. Rev. Mol. Cell Biol 2007, 8:983-994.
19. Kanwal R., Gupta S. Epigenetic modifications in cancer. Clin. Genet 2012, 81:303-311.
20. Bradbury E.M. Reversible histone modifications and the chromosome cell cycle. Bioessays 1992, 14:9-16.
21. Halmer L., Gruss C. Effects of cell cycle dependent histone H1 phosphorylation on chromatin structure and chromatin replication. Nucleic Acids Res 1996, 24:1420-1427.
22. Weake V.M., Workman J.L. Histone ubiquitination: triggering gene activity. Mol. Cell 2008, 29:653-663.
23. Jason L.J., Moore S.C., Lewis J.D., Lindsey G., Ausio J. Histone ubiquitination: a tagging tail unfolds?. Bioessays 2002, 24:166-174.
24. Shiio Y., Eisenman R.N. Histone sumoylation is associated with transcriptional repression. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:13225-13230.
25. Annalisa I., Robert S. The role of linker histone H1 modifications in the regulation of gene expression and chromatin dynamics. Biochim. Biophys. Acta 2015, 10.1016/j.bbagrm.2015.09.003.
26. Maleszewska M., Kaminska B. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development. Future Oncol 2015, 11:2587-2601.
27. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
28. Vahid F., Zand H., Nosrat-Mirshekarlou E., Najafi R., Hekmatdoost A. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review. Gene 2015, 562:8-15.
29. Consortium E.P., Birney E., Stamatoyannopoulos J.A., Dutta A., Guigo R., Gingeras T.R., et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007, 447:799-816.
30. Martin C., Zhang Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol 2005, 6:838-849.
31. Guenther M.G., Levine S.S., Boyer L.A., Jaenisch R., Young R.A. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007, 130:77-88.
32. Krivtsov A.V., Feng Z., Lemieux M.E., Faber J., Vempati S., Sinha A.U., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
33. Steger D.J., Lefterova M.I., Ying L., Stonestrom A.J., Schupp M., Zhuo D., et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol. Cell. Biol 2008, 28:2825-2839.
34. Edmunds J.W., Mahadevan L.C., Clayton A.L. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J. 2008, 27:406-420.
35. Heintzman N.D., Stuart R.K., Hon G., Fu Y., Ching C.W., Hawkins R.D., et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet 2007, 39:311-318.
36. Koch C.M., Andrews R.M., Flicek P., Dillon S.C., Karaoz U., Clelland G.K., et al. The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res 2007, 17:691-707.
37. American Association for Cancer Research Human Epigenome Task Force; European Union, Network of Excellence, Scientific Advisory Board Moving AHEAD with an international human epigenome project. Nature 2008, 454:711-715.
38. Loeb L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991, 51:3075-3079.
39. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
40. McKenna E.S., Sansam C.G., Cho Y.J., Greulich H., Evans J.A., Thom C.S., et al. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol. Cell. Biol 2008, 28:6223-6233.
41. Zhang W., Glockner S.C., Guo M., Machida E.O., Wang D.H., Easwaran H., et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 2008, 68:2764-2772.
42. Suzuki H., Watkins D.N., Jair K.W., Schuebel K.E., Markowitz S.D., Chen W.D., et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet 2004, 36:417-422.
43. Chen R.Z., Pettersson U., Beard C., Jackson-Grusby L., Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998, 395:89-93.
44. Baylin S., Bestor T.H. Altered methylation patterns in cancer cell genomes: cause or consequence?. Cancer Cell 2002, 1:299-305.
45. Sadikovic B., Al-Romaih K., Squire J.A., Zielenska M. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr. Genomics 2008, 9:394-408.
46. Chik F., Szyf M., Rabbani S.A. Role of epigenetics in cancer initiation and progression. Adv. Exp. Med. Biol 2011, 720:91-104.
47. Shih Ie M., Chen L., Wang C.C., Gu J., Davidson B., Cope L., et al. Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am. J. Obstet. Gynecol 2010, 203:584 e581-22.
48. Zelic R., Fiano V., Grasso C., Zugna D., Pettersson A., Gillio-Tos A., et al. Global DNA hypomethylation in prostate cancer development and progression: a systematic review. Prostate Cancer Prostatic Dis 2015, 18:1-12.
49. Liu X., Wang X., Zhang J., Lam E.K., Shin V.Y., Cheng A.S., et al. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 2010, 29:442-450.
50. Sun W., Liu Y., Glazer C.A., Shao C., Bhan S., Demokan S., et al. TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin. Cancer Res 2010, 16:857-866.
51. Naganuma K., Hatta M., Ikebe T., Yamazaki J. Epigenetic alterations of the keratin 13 gene in oral squamous cell carcinoma. BMC Cancer 2014, 14:988.
52. Chen M., Zhang J., Li N., Qian Z., Zhu M., Li Q., et al. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS ONE 2011, 6:e25564.
53. Mehta A., Dobersch S., Romero-Olmedo A.J., Barreto G. Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev 2015, 34:229-241.
54. Hurt E.M., Thomas S.B., Peng B., Farrar W.L. Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines. Br. J. Cancer 2007, 97:1116-1123.
55. Kim T.D., Shin S., Berry W.L., Oh S., Janknecht R. The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J. Cell. Biochem 2012, 113:1368-1376.
56. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
57. Liu L., Ling X., Liang H., Gao Y., Yang H., Shao J., et al. Hypomethylation mediated by decreased DNMTs involves in the activation of proto-oncogene MPL in TK6 cells treated with hydroquinone. Toxicol. Lett 2012, 209:239-245.
58. Pecina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 2003, 3:17.
59. Zeng W., Zhu J., Shan L., Han Z., Aerxiding P., Quhai A., et al. The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review. Drug Des. Devel. Ther 2015, 9:2149-2157.
60. Karczmarski J., Rubel T., Paziewska A., Mikula M., Bujko M., Kober P., et al. Histone H3 lysine 27 acetylation is altered in colon cancer. Clin. Proteomics 2014, 11:24.
61. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet 2005, 37:391-400.
62. Kondo Y., Shen L., Issa J.P. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol. Cell. Biol 2003, 23:206-215.
63. Amelio I., Antonov A.A., Catani M.V., Massoud R., Bernassola F., Knight R.A., et al. TAp73 promotes anabolism. Oncotarget 2014, 5:12820-12934.
64. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
65. Wang X., Jin H. The epigenetic basis of the Warburg effect. Epigenetics 2010, 5:566-568.
66. el-Maghrabi M.R., Lange A.J., Jiang W., Yamagata K., Stoffel M., Takeda J., et al. Human fructose-1,6-bisphosphatase gene (FBP1): exon-intron organization, localization to chromosome bands 9q22.2-q22.3, and mutation screening in subjects with fructose-1,6-bisphosphatase deficiency. Genomics 1995, 27:520-525.
67. Tillmann H., Stein S., Liehr T., Eschrich K. Structure and chromosomal localization of the human and mouse muscle fructose-1,6-bisphosphatase genes. Gene 2000, 247:241-253.
68. Li H., Wang J., Xu H., Xing R., Pan Y., Li W., et al. Decreased fructose-1,6-bisphosphatase-expression promotes glycolysis and growth in gastric cancer cells. Mol. Cancer 2013, 12:110.
69. Yamamoto T., Takano N., Ishiwata K., Ohmura M., Nagahata Y., Matsuura T., et al. Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway. Nat. Commun 2014, 5:3480.
70. Desai S., Ding M., Wang B., Lu Z., Zhao Q., Shaw K., et al. Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 2014, 5:8202-8210.
71. Brown N.J., Higham S.E., Perunovic B., Arafa M., Balasubramanian S., Rehman I. Lactate dehydrogenase-is silenced by promoter methylation in a high frequency of human breast cancers. PLoS ONE 2013, 8:e57697.
72. Huang G., Lu H., Hao A., Ng D.C., Ponniah S., Guo K., et al. GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I. Mol. Cell. Biol 2004, 24:8447-8456.
73. Zhang X.Y., Li M., Sun K., Chen X.J., Meng J., Wu L., et al. Decreased expression of GRIM-19 by DNA hypermethylation promotes aerobic glycolysis and cell proliferation in head and neck squamous cell carcinoma. Oncotarget 2015, 6:101-115.
74. Wang R., He W., Li Z., Chang W., Xin Y., Huang T. Caveolin-functions as a key regulator of 17beta-estradiol-mediated autophagy and apoptosis in BT474 breast cancer cells. Int. J. Mol. Med 2014, 34:822-827.
75. Martinez-Outschoorn U.E., Sotgia F., Lisanti M.P. Caveolae and signalling in cancer. Nat. Rev. Cancer 2015, 15:225-237.
76. Ha T.K., Her N.G., Lee M.G., Ryu B.K., Lee J.H., Han J., et al. Caveolin-increases aerobic glycolysis in colorectal cancers by stimulating HMGA1-mediated GLUT3 transcription. Cancer Res 2012, 72:4097-4109.
77. Tahir S.A., Yang G., Goltsov A., Song K.D., Ren C., Wang J., et al. Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res 2013, 73:1900-1911.
78. Zhang C., Zhang Z., Zhu Y., Qin S. Glucose-6-phosphate dehydrogenase: a biomarker and potential therapeutic target for cancer. Anticancer Agents Med. Chem 2014, 14:280-289.
79. Wang J., Yuan W., Chen Z., Wu S., Chen J., Ge J., et al. Overexpression of G6PD is associated with poor clinical outcome in gastric cancer. Tumour Biol 2012, 33:95-101.
80. Kuo W., Lin J., Tang T.K. Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int. J. Cancer 2000, 85:857-864.
81. Bokun R., Bakotin J., Milasinovic D. Semiquantitative cytochemical estimation of glucose-6-phosphate dehydrogenase activity in benign diseases and carcinoma of the breast. Acta Cytol 1987, 31:249-252.
82. Hu T., Li Y.S., Chen B., Chang Y.F., Liu G.C., Hong Y., et al. Elevated glucose-6-phosphate dehydrogenase expression in the cervical cancer cases is associated with the cancerigenic event of high-risk human papillomaviruses. Exp. Biol. Med. (Maywood) 2015, 240:1287-1297.
83. Tsouko E., Khan A.S., White M.A., Han J.J., Shi Y., Merchant F.A., et al. Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis 2014, 3:e103.
84. Stanton R.C. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life 2012, 64:362-369.
85. Du W., Jiang P., Mancuso A., Stonestrom A., Brewer M.D., Minn A.J., et al. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat. Cell Biol 2013, 15:991-1000.
86. Franco R., Schoneveld O., Georgakilas A.G., Panayiotidis M.I. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett 2008, 266:6-11.
87. Wu Q., Ni X. ROS-mediated DNA methylation pattern alterations in carcinogenesis. Curr. Drug Targets 2015, 16:13-19.
88. Hitchler M.J., Wikainapakul K., Yu L., Powers K., Attatippaholkun W., Domann F.E. Epigenetic regulation of manganese superoxide dismutase expression in human breast cancer cells. Epigenetics 2006, 1:163-171.
89. Ghoshal K., Majumder S., Li Z., Dong X., Jacob S.T. Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation. J. Biol. Chem 2000, 275:539-547.
90. Tada M., Yokosuka O., Fukai K., Chiba T., Imazeki F., Tokuhisa T., et al. Hypermethylation of NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in human hepatocellular carcinoma. J. Hepatol 2005, 42:511-519.
91. Wu J.C., Wang F.Z., Tsai M.L., Lo C.Y., Badmaev V., Ho C.T., et al. Se-Allylselenocysteine induces autophagy by modulating the AMPK/mTOR signaling pathway and epigenetic regulation of PCDH17 in human colorectal adenocarcinoma cells. Mol. Nutr. Food Res 2015, 59(12):2511-2522.
92. Farooqi A.A., Fayyaz S., Hou M.F., Li K.T., Tang J.Y., Chang H.W. Reactive oxygen species and autophagy modulation in non-marine drugs and marine drugs. Mar. Drugs 2014, 12:5408-5424.
93. Lapierre L.R., Kumsta C., Sandri M., Ballabio A., Hansen M. Transcriptional and epigenetic regulation of autophagy in aging. Autophagy 2015, 11:867-880.
94. Rajendran P., Ho E., Williams D.E., Dashwood R.H. Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin. Epigenetics 2011, 3:4.
95. Yang J.J., Tao H., Deng Z.Y., Lu C., Li J. Non-coding RNA-mediated epigenetic regulation of liver fibrosis. Metabolism 2015, 64(11):1386-1394.
96. Tao H., Yang J.J., Shi K.H. Non-coding RNAs as direct and indirect modulators of epigenetic mechanism regulation of cardiac fibrosis. Expert Opin. Ther. Targets 2015, 19:707-716.
97. Venkataraman S., Alimova I., Fan R., Harris P., Foreman N., Vibhakar R. MicroRNA 128a increases intracellular ROS level by targeting Bmi-and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS ONE 2010, 5:e10748.
98. Guo X., Xia J., Yan J. Promoter methylated microRNAs: potential therapeutic targets in gastric cancer. Mol. Med. Rep 2015, 11:759-765.
99. Shen J., Wang S., Siegel A.B., Remotti H., Wang Q., Sirosh I., et al. Genome-wide expression of microRNAs is regulated by DNA methylation in hepatocarcinogenesis. Gastroenterol. Res. Pract 2015, 2015:230642.
100. Cheung H.H., Lee T.L., Davis A.J., Taft D.H., Rennert O.M., Chan W.Y. Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br. J. Cancer 2010, 102:419-427.
101. Chen B.F., Suen Y.K., Gu S., Li L., Chan W.Y. A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor. Sci. Rep 2014, 4:6413.
102. O'Hagan H.M., Wang W., Sen S., Destefano Shields C., Lee S.S., Zhang Y.W., et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 2011, 20:606-619.
103. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med 2011, 17:330-339.
104. Kelly T.K., De Carvalho D.D., Jones P.A. Epigenetic modifications as therapeutic targets. Nat. Biotechnol 2010, 28:1069-1078.
105. Vaish V., Khare T., Verma M., Khare S. Epigenetic therapy for colorectal cancer. Methods Mol. Biol 2015, 1238:771-782.
106. Perry A.S., Watson R.W., Lawler M., Hollywood D. The epigenome as a therapeutic target in prostate cancer. Nat. Rev. Urol 2010, 7:668-680.
107. Huang R., Ding P., Yang F. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review. Drug Des. Devel. Ther 2015, 9:5277-5285.
108. Yu Q., Guo Q., Chen L., Liu S. Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review. Drug Des. Devel. Ther 2015, 9:2171-2178.
109. Erdmann A., Halby L., Fahy J., Arimondo P.B. Targeting DNA methylation with small molecules: what's next?. J. Med. Chem 2015, 58:2569-2583.
110. Pleyer L., Greil R. Digging deep into "dirty" drugs - modulation of the methylation machinery. Drug Metab. Rev 2015, 47:252-279.
111. Lakshmaiah K.C., Jacob L.A., Aparna S., Lokanatha D., Saldanha S.C. Epigenetic therapy of cancer with histone deacetylase inhibitors. J. Cancer Res. Ther. (Manch.) 2014, 10:469-478.
112. Olzscha H., Sheikh S., La Thangue N.B. Deacetylation of chromatin and gene expression regulation: a new target for epigenetic therapy. Crit. Rev. Oncog 2015, 20:1-17.
113. Tan S., Liu Z.P. Natural products as zinc-dependent histone deacetylase inhibitors. ChemMedChem 2015, 10:441-450.
114. Jones P., Steinkuhler C. From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents. Curr. Pharm. Des 2008, 14:545-561.
115. Farooqi A.A., Tang J.Y., Li R.N., Ismail M., Chang Y.T., Shu C.W., et al. Epigenetic mechanisms in cancer: push and pull between kneaded erasers and fate writers. Int. J. Nanomedicine 2015, 10:3183-3191.
116. Kim B., Hong J. An overview of naturally occurring histone deacetylase inhibitors. Curr. Top. Med. Chem 2015, 14:2759-2782.
117. Chou R.H., Wang Y.N., Hsieh Y.H., Li L.Y., Xia W., Chang W.C., et al. EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4. Dev. Cell 2014, 30:224-237.
118. Houtkooper R.H., Pirinen E., Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol 2012, 13:225-238.
119. Chang H.C., Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol. Metab 2014, 25:138-145.
120. Lugrin J., Ciarlo E., Santos A., Grandmaison G., dos Santos I., Le Roy D., et al. The sirtuin inhibitor cambinol impairs MAPK signaling, inhibits inflammatory and innate immune responses and protects from septic shock. Biochim. Biophys. Acta 1833, 2013:1498-1510.
121. Gertz M., Fischer F., Nguyen G.T., Lakshminarasimhan M., Schutkowski M., Weyand M., et al. Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E2772-E2781.
122. Selvi B.R., Cassel J.C., Kundu T.K., Boutillier A.L. Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases. Biochim. Biophys. Acta 2010, 1799:840-853.
123. Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K., Chin S.F., et al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet 2000, 24:300-303.
124. Bandyopadhyay D., Okan N.A., Bales E., Nascimento L., Cole P.A., Medrano E.E. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res 2002, 62:6231-6239.
125. Oike T., Komachi M., Ogiwara H., Amornwichet N., Saitoh Y., Torikai K., et al. C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe. Radiother. Oncol 2014, 111:222-227.
126. Roth S.Y., Denu J.M., Allis C.D. Histone acetyltransferases. Annu. Rev. Biochem 2001, 70:81-120.
127. Dekker F.J., Haisma H.J. Histone acetyl transferases as emerging drug targets. Drug Discov. Today 2009, 14:942-948.
128. Plass C., Pfister S.M., Lindroth A.M., Bogatyrova O., Claus R., Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet 2013, 14:765-780.
129. Chou R.H., Chiu L., Yu Y.L., Shyu W.C. The potential roles of EZH2 in regenerative medicine. Cell Transplant 2015, 24:313-317.
130. Volkel P., Dupret B., Le Bourhis X., Angrand P.O. Diverse involvement of EZH2 in cancer epigenetics. Am. J. Transl. Res 2015, 7:175-193.
131. McCabe M.T., Ott H.M., Ganji G., Korenchuk S., Thompson C., Van Aller G.S., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
132. Xu B., Konze K.D., Jin J., Wang G.G. Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp. Hematol 2015, 43:698-712.
133. Nguyen A.T., Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev 2011, 25:1345-1358.
134. Jones P.A. At the tipping point for epigenetic therapies in cancer. J. Clin. Invest 2014, 124:14-16.
135. Daigle S.R., Olhava E.J., Therkelsen C.A., Basavapathruni A., Jin L., Boriack-Sjodin P.A., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013, 122:1017-1025.
136. Klaus C.R., Iwanowicz D., Johnston D., Campbell C.A., Smith J.J., Moyer M.P., et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J. Pharmacol. Exp. Ther 2014, 350:646-656.
137. Chen C.W., Koche R.P., Sinha A.U., Deshpande A.J., Zhu N., Eng R., et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat. Med 2015, 21:335-343.
138. Zagni C., Chiacchio U., Rescifina A. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment. Curr. Med. Chem 2013, 20:167-185.
139. Chi P., Allis C.D., Wang G.G. Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 2010, 10:457-469.
140. Teperino R., Schoonjans K., Auwerx J. Histone methyl transferases and demethylases; can they link metabolism and transcription?. Cell Metab 2010, 12:321-327.
141. Black J.C., Allen A., Van Rechem C., Forbes E., Longworth M., Tschop K., et al. Conserved antagonism between JMJD2A/KDM4A and HP1gamma during cell cycle progression. Mol. Cell 2010, 40:736-748.
142. Guerra-Calderas L., Gonzalez-Barrios R., Herrera L.A., Cantu de Leon D., Soto-Reyes E. The role of the histone demethylase KDM4A in cancer. Cancer Genet 2015, 208:215-224.
143. Shin S., Janknecht R. Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem. Biophys. Res. Commun 2007, 359:742-746.
144. Kogure M., Takawa M., Cho H.S., Toyokawa G., Hayashi K., Tsunoda T., et al. Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition. Cancer Lett 2013, 336:76-84.
145. Berry W.L., Shin S., Lightfoot S.A., Janknecht R. Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int. J. Oncol 2012, 41:1701-1706.
146. Ding X., Pan H., Li J., Zhong Q., Chen X., Dry S.M., et al. Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis. Sci. Signal 2013, 6:ra28.1-ra28.13. S0-15.
147. Maes T., Carceller E., Salas J., Ortega A., Buesa C. Advances in the development of histone lysine demethylase inhibitors. Curr. Opin. Pharmacol 2015, 23:52-60.
148. Zheng Y.C., Ma J., Wang Z., Li J., Jiang B., Zhou W., et al. A systematic review of histone lysine-specific demethylase 1 and its inhibitors. Med. Res. Rev 2015, 35:1032-1071.
149. Carter B.Z., Mak P.Y., Mak D.H., Shi Y., Qiu Y., Bogenberger J.M., et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J. Natl Cancer Inst 2014, 106:djt440.
150. Chik F., Machnes Z., Szyf M. Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S-adenosyl methionine and the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Carcinogenesis 2014, 35:138-144.
151. Groselj B., Sharma N.L., Hamdy F.C., Kerr M., Kiltie A.E. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br. J. Cancer 2013, 108:748-754.
152. Zhang F., Zhang T., Teng Z.H., Zhang R., Wang J.B., Mei Q.B. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol. Ther 2009, 8:823-831.
153. Oike T., Ogiwara H., Torikai K., Nakano T., Yokota J., Kohno T. Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining. Int. J. Radiat. Oncol. Biol. Phys 2012, 84:815-821.
154. Yeh C.C., Yang J.I., Lee J.C., Tseng C.N., Chan Y.C., Hseu Y.C., et al. Anti-proliferative effect of methanolic extract of Gracilaria tenuistipitata on oral cancer cells involves apoptosis, DNA damage, and oxidative stress. BMC Complement. Altern. Med 2012, 12:142.
155. Yeh C.C., Tseng C.N., Yang J.I., Huang H.W., Fang Y., Tang J.Y., et al. Antiproliferation and induction of apoptosis in Ca9-22 oral cancer cells by ethanolic extract of Gracilaria tenuistipitata. Molecules 2012, 17:10916-10927.
156. Yen Y.H., Farooqi A.A., Li K.T., Butt G., Tang J.Y., Wu C.Y., et al. Methanolic extracts of Solieria robusta inhibits proliferation of oral cancer Ca9-22 cells via apoptosis and oxidative stress. Molecules 2014, 19:18721-18732.
157. Yen C.Y., Chiu C.C., Haung R.W., Yeh C.C., Huang K.J., Chang K.F., et al. Antiproliferative effects of goniothalamin on Ca9-22 oral cancer cells through apoptosis, DNA damage and ROS induction. Mutat. Res 2012, 747:253-258.
158. Chiu C.C., Haung J.W., Chang F.R., Huang K.J., Huang H.M., Huang H.W., et al. Golden berry-derived 4beta-hydroxywithanolide E for selectively killing oral cancer cells by generating ROS, DNA damage, and apoptotic pathways. PLoS ONE 2013, 8:e64739.
159. Phang J.M., Liu W., Hancock C. Bridging epigenetics and metabolism: role of non-essential amino acids. Epigenetics 2013, 8:231-236.
160. Ferrari A., Fiorino E., Giudici M., Gilardi F., Galmozzi A., Mitro N., et al. Linking epigenetics to lipid metabolism: focus on histone deacetylases. Mol. Membr. Biol 2012, 29:257-266.
161. Poirier S., Samami S., Mamarbachi M., Demers A., Chang T.Y., Vance D.E., et al. The epigenetic drug 5-azacytidine interferes with cholesterol and lipid metabolism. J. Biol. Chem 2014, 289:18736-18751.